Citi is raising its estimates on Endo Pharmaceuticals Holdings Inc. ENDP on the following elements:
“1) An earlier acquisition close,” Citi writes. “2) A lower blended rate on debt (4.4% vs. prior 5.0% est.); 3) $400M retirement in existing Term A loans (TLA); 4) $170M smaller use of cash on hand; offset by 5) higher acquisition-related debt ($3.1B vs. $2.6B est.) & $10M lower '11 sales (due to AMS voluntary recall of its artificial urinary sphincter).
“Our projected annual AMS sales growth is below AMS's projected 10%-12% (disclosed in its 6/2/11 proxy). Our blended interest rate of 4.4% includes: $500M in 7% notes due'19, $400M in 7.25% notes due'22, $1.5B in TLA (4% est.) & $700M in TLB (3% est.).”
Endo Pharmaceuticals closed Friday at $39.14.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in